Navigation Links
Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
Date:11/13/2008

with a corresponding negative predictive value of 99.1%. Patients with CIN2 are at risk of developing cervical cancer, however this risk is not as high as it is for those diagnosed with CIN3.

-- When compared to the ASC-US/LSIL Triage Study (ALTS), the Cervista HPV high-risk test has a comparable specificity to the test used in that study. The ALTS trial is the best comparative trial for the Cervista HPV high-risk trial based on similarities in trial design.

The Cervista HPV high-risk test has additional advantages including:

-- The Cervista HPV high-risk test has demonstrated a low indeterminate rate (i.e. inability of the test to give a result) of less than 1% and no cross reactivity with commonly reported low-risk HPV types.

-- An internal control that minimizes the potential for a false negative result due to insufficient sample cellularity.

-- Small volume of liquid-based cytology sample required for HPV testing. Hologic believes that this will reduce the percentage of "quantity not sufficient" samples that are burdensome to the lab, physicians and patients alike.

-- Workflow advantages for the laboratory. The Cervista HPV high-risk test requires minimal hands on time, and yields a rapid time to results.

In addition to the results for the Cervista HPV high-risk test, Hologic also announced today the clinical trial results for the Cervista 16/18 test, a genotyping test for high-risk HPV types 16 and 18, which are responsible for approximately 70% of all cervical cancers. The Cervista(R) 16/18 test is also pending FDA approval. Similar to the high risk screening test, the Cervista 16/18 test results were compared to CIN2 and CIN3 clinical end-points. Two potentially important findings were Negative Predictive Values for 99.5% for CIN3 and 97.7% for CIN2+. Recent consensus guidelines released by the American Society for Colposcopy and Cervical Pathology (ASCCP) in 2007 stated that "...it would be reasonable to util
'/>"/>

SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
2. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
3. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
4. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
5. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
6. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
7. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
8. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Immunosyn Corporation Releases SF-1019 Study Results
11. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... 15 West Pharmaceutical Services, Inc. (NYSE: ... Directors has approved payment of the first-quarter 2010 cash ... paid on February 3, 2010 to shareholders of record ... ,, West is a global manufacturer of components ... seals for vials, and closures and disposable components used ...
(Date:12/15/2009)... 15 SRI International, an independent nonprofit ... of U.S. patent 7,592,021 for a new bioadhesive ... drugs through the human body,s mucous membranes. This ... allows for a much longer release time compared ... Transmucosal delivery is an effective means to introduce ...
(Date:12/15/2009)... SINGAPORE, Dec. 15 ... that it has completed the previously announced ... manufacturer of disposable medical devices ranging from ... surgery. Through its medical segment, Flextronics provides ... device, medical equipment, and pharmaceutical customers. Terms ...
Breaking Medicine Technology:SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 2SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 3SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 4SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 5Flextronics Completes SloMedical Acquisition 2Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 1Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 2Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 3Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 4Macomb County Health Department Schedules Communitywide H1N1 Flu Vaccine Clinic Nov 24 61652 1Macomb County Health Department Schedules Communitywide H1N1 Flu Vaccine Clinic Nov 24 61652 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 1National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 3
... is Designed to Differentiate Squamous From, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying ... of 90 ... Percent., Accurate Diagnosis is Important ... Potential Higher Rates of Severe or Fatal Hemorrhage in Patients With Squamous ...
... 2 DermaGen AB today announced a,cash injection from ... Development and Ostersjostiftelsen. The capital will be used for,the ... be used to initiate a clinical phase 2a study ... has already received approval, and,to further develop the company,s ...
Other Medicine Technology:Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 2Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 3Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 4Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 5Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 6Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 7DermaGen AB Receives Over 1 Million Euros From a New Share Issue 2DermaGen AB Receives Over 1 Million Euros From a New Share Issue 3
(Date:12/16/2009)... free nationwide confidential legal consultations for users of Paxil who ... Defects, Attempted Suicide, Suicide and Addiction Issues. Individuals suffering from ... go to the firm’s website at http://www.ennislaw.com and ... ... (PRWEB) December 16, 2009 -- Bloomberg news ...
(Date:12/16/2009)... Foods will be carrying Dr. Shapio,s Help Hair Shake in all of ... ... (PRWEB) December 16, 2009 -- Dr. Larry Shapiro, hair transplant ... Foods stores will be carrying the Help Hair Whey Protein Shake. ... suitable as an adjunct for weight loss programs, working out and muscle ...
(Date:12/15/2009)... successfully developed a new electrophoretic method for detecting ... The technique, using SARCOSYL-PAGE, has specifically enhanced ... performance characteristics of SDS-PAGE for detecting other EPOs. ... grant from the World Anti-Doping Agency (WADA), appear ... and Analysis published by Wiley-Blackwell. , MIRCERA ...
(Date:12/15/2009)... SUMMARY: The U.S. Senate today rejected an ... Act that would have helped make prescription drugs ... legal importation of lower priced drugs from abroad. ... by Senators Dorgan, Snowe, McCain, Grassley and Stabenow, ... down the skyrocketing costs of prescription drugs. ,, ...
(Date:12/15/2009)... Bulletin Board: SNKTY), a Life Sciences company engaged in the research, development and commercialization of ... three resolutions that the Company had proposed at the Annual General Meeting of Shareholders held ... of Votes ... Non-, Matter ... For Against ...
Breaking Medicine News(10 mins):Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 3Health News:Florida Whole Foods Stores to Carry Dr. Lawrence Shapiro's Help Hair Shake 2Health News:Researchers discover novel method for detecting MIRCERA 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3
... the human growth hormone (HGH) industry approaches $2 ... athletic performance, anti-aging and stimulating growth. Unfortunately, many ... of independent review organizations (IROs) whose members see ... medical necessity of growth hormone therapies ( www.nairo.org ...
... Network,s CIO on Helping Organizations Protect Medical Records and Comply ... ... Scottsdale, Ariz. (PRWEB) April 14, 2009 -- With an increasing ... of new challenges to implement administrative, technical and physical security ...
... flow measurement and control provider, announced that it has acquired ... Key Instruments is a flow meter manufacturer based in Trevose, ... flow meters, glass tube flow meters, electronic flow meters, and ... applications. , ...
... 14 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... of a New Drug Application (NDA) to the U.S. ... relapsed or refractory aggressive non-Hodgkin,s lymphoma (NHL). CTI expects ... priority review which if granted could lead to an ...
... allow BlackBerry® devices to securely connect to ActiveSync supported email ... or businesses that require ActiveSync for their mobility solution such ... Suite or the CommuniGate Pro Server. , ... ...
... and PLANO, Texas, April 13 Botox,s arch-nemesis, ... the U.S. cosmetics ring at any moment; whether ... slightly unfamiliar European cousin remains to be seen, ... a significant potential cost savings, is certainly provocative. ...
Other Medicine News:Health News:IROs Help Determine Medical Necessity of Growth Hormone Therapy 2Health News:Lumension Webinar Focuses on How to Protect Medical Records, Ensure HIPAA Compliance and Improve Productivity 2Health News:Lumension Webinar Focuses on How to Protect Medical Records, Ensure HIPAA Compliance and Improve Productivity 3Health News:Brooks Instrument Acquires Flow Products Supplier Key Instruments 2Health News:Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone 2Health News:Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone 3Health News:Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone 4Health News:NotifySync™ Provides BlackBerry a Direct Connection to Any Email Platform Supporting Microsoft ActiveSync 2Health News:Botox(R) vs. Reloxin(R) -- the Wrinkle Titans Poised for Battle 2Health News:Botox(R) vs. Reloxin(R) -- the Wrinkle Titans Poised for Battle 3Health News:Botox(R) vs. Reloxin(R) -- the Wrinkle Titans Poised for Battle 4
MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... ZOOM® Dual Power is a microprocessor-controlled ... both high voltage/low current and high ... voltage/low current section is ideal for ... DNA sequencing applications. The low voltage/high ...
... Power Supply is designed specifically ... extensive programming capabilities, including eight ... for you to set to ... intuitive PowerEase® interface is faster ...
Medicine Products: